Boston Scientific Corporation (BSX) on Decifer

Decifer ranks BSX number 71 of 277 tracked names on durable business quality.

Why it ranks here

• It earns solid returns on the money it puts to work, around 9% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is growing about 20% a year, profits grew 56% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• And its own insiders have been buying.
• Revenue growing about 20% a year with profits up 56% and insiders buying make this a strong business, but momentum of 0 out of 35 and no stated growth role hold it back.

The current read

The evidence on BSX points in two directions at once: fresh news: Boston Scientific Q2 Earnings Call Highlights, while options activity is unusually heavy with positioning leaning toward downside. Until one side gives way, treat the picture as unresolved rather than a clean story.

Themes

• Healthcare, Biotech & Devices: Boston Scientific Corporation operates in medical - devices. That places it inside the Healthcare, Biotech & Devices story.

Read the full BSX research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.